Good morning, everyone. Thank you for being here. My name is Steve O'Loughlin. I'm the Chief Financial Officer for Actinium Pharmaceuticals. Actinium is listed on the NYSE under the symbol ATNM, and we are focused on pioneering targeted radiotherapies for patients with cancers that have high unmet needs. Just a reminder before I begin, disclaimer and safe harbor, as I will be making forward-looking statements this morning. I would encourage everyone to review our filings, which may be updated annually from time to time on the SEC and investor deck. In 2025, we anticipate it to be an exciting year for Actinium Pharmaceuticals. We have several clinical programs which have recently been revitalized and have a revamped strategy that we are now taking forward and expect to deliver multiple clinical, regulatory, and strategic milestones this year. I will focus this morning on our lead clinical program, Actimab-A, which we are developing ourselves. Also, we're developing Actimab-A under a cooperative research and development agreement, or CRADA, with the National Cancer Institute. We have recently started a trial in frontline acute myeloid leukemia and expect other trials to start, including a pivotal phase II/III trial that I will highlight in subsequent slides. Recently, we have also announced that we are starting to explore Actimab-A in solid tumor indications in combination with an anti-PD-1 specifically Keytruda that we're currently working on. Our Iomab-ACT program is being advanced to increase access and improve patient outcomes to myeloid therapies such as CAR-T and gene therapy. We have two clinical trials that will be active in 2025, with data from those trials expected in the second half of the year. In the targeted radiotherapy space, we have invested in our capabilities and our R&D infrastructure. We do have an enhanced R&D that has generated preclinical data to support our clinical programs, as well as supported pipeline advancement. We have two abstracts that have been accepted for presentation at the upcoming AACR conference later this month. We have recently announced that we intend to build our own in-house radiotherapy manufacturing facility starting this year. Perhaps most importantly, we finished 2024 with approximately $72.9 million in cash and cash equivalents on the balance sheet, which we anticipate will fund our operations into mid-2027. We have the runway to execute on this strategy and our revitalized programs. Moving ahead, this involved an agreement with the NCI. The first trial initiated under this CRADA is in frontline AML, so patients newly diagnosed, which is a large market opportunity. One of the standards of care is what's known as venetoclax plus HMA. venetoclax is a drug that is marketed by AbbVie and Roche and is used extensively in the AML. We will be adding Actimab-A to the venetoclax HMA therapy, so looking at this as a backbone in these newly diagnosed patients. This trial has been initiated. It is active, and we expect initial data from this trial by the end of this year. We are excited about the opportunity to expand the market potential for Actimab-A into the frontline setting. On the left, you can see there are broad development opportunities for CRADA and are actively advancing Actimab-A in combination with Keytruda and Opdivo in solid tumors, which I will now highlight in more detail. Actimab-A targets CD33, primarily known as a blood cancer target. However, our team was looking at the patients treated with Keytruda and Opdivo, the PD-1 inhibitors, which are the largest selling oncology drugs. There's extensive research being done into why do these patients stop responding or why do they have suboptimal responses. One of the things that's been identified is the tumor kind of counteracts the PD-1 inhibitors, and in particular, an immune cell subtype called MDSCs, or myeloid-derived suppressor cells. MDSCs are overexpressed in a significant number of patients with multiple tumor types. Those MDSCs express CD33 just like blood cancer cells, deplete them, and in doing so, have the potential to resensitize these solid tumors to PD-1 inhibitors. There have been studies published that evaluate the role of MDSCs in outcomes. This study, in particular, looked at patients with non-small cell lung cancer and looked at patients with high levels or low levels of MDSCs. What the investigators here published is that in the patients who had high levels of MDSC, none of those patients had a response at all. They looked at survival outcomes. In the patients who had high MDSCs, their progression-free survival was 1.94 months versus 8.39 months. Obviously, a significant difference. Looking at overall survival, the patients with high MDSCs had a 3.03-month median overall survival compared to 15 months for the patients with low MDSCs. We believe that supports, along with our preclinical data, advancing this forward. We have announced we have initiated a clinical trial program. There will be multiple trials conducted under this. We will look at Actimab-A in combination with Keytruda and Opdivo in non-small cell lung cancer, as well as head and neck cancer. We expect initial data from these studies to start in the second half of this year. We will be looking at safety, obviously, but also looking at efficacy endpoints, including rates of response, progression-free survival, and overall survival. We will also be looking at biomarkers. We believe that depleting MDSCs can improve response to PD-1 checkpoint inhibitors. A program that we're very excited about internally that we have just recently announced is our newest program, so ATNM-400. This is an Actinium-225-based radiotherapy for prostate cancer. Much of the field in radiotherapy has focused on PSMA as the target for prostate cancer. This is a non-PSMA radiotherapy that we believe is first in class and next generation. Our team has produced preclinical data. It has been accepted for presentation. What we have seen is a single-dose efficacy with as high as 99.8% tumor growth inhibition with a single dose of ATNM-400. We've shown that it selectively binds to prostate cancer cells. We have also looked at prostate cancer models that are resistant to Pluvicto. Pluvicto is the approved prostate cancer radiotherapy that last year generated over $1 billion in sales. We look forward to presenting additional data from this at ASTRO. This is a program internally that we are quite excited about. Our Iomab program includes Iomab-ACT and Iomab-B.